Neurocrine Biosciences, Inc. (0K6R.L)
USD 109.75
(1.72%)
USD 109.75
(1.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 250.9 Million USD | 0.76% |
| 2022 | 249 Million USD | 26.46% |
| 2021 | 196.9 Million USD | -38.26% |
| 2020 | 318.9 Million USD | 45.52% |
| 2019 | 219.14 Million USD | 493.98% |
| 2018 | 36.89 Million USD | 128.09% |
| 2017 | -131.36 Million USD | 10.86% |
| 2016 | -147.37 Million USD | -56.44% |
| 2015 | -94.2 Million USD | -46.25% |
| 2014 | -64.41 Million USD | -29.66% |
| 2013 | -49.67 Million USD | -3530.8% |
| 2012 | 1.44 Million USD | -95.73% |
| 2011 | 33.92 Million USD | 347.21% |
| 2010 | -13.72 Million USD | 74.43% |
| 2009 | -53.67 Million USD | 38.52% |
| 2008 | -87.29 Million USD | 58.87% |
| 2007 | -212.24 Million USD | -87.3% |
| 2006 | -113.31 Million USD | -351.97% |
| 2005 | -25.07 Million USD | 52.09% |
| 2004 | -52.33 Million USD | 10.98% |
| 2003 | -58.78 Million USD | 43.26% |
| 2002 | -103.61 Million USD | -136.12% |
| 2001 | -43.88 Million USD | -23.26% |
| 2000 | -35.6 Million USD | -78.9% |
| 1999 | -19.9 Million USD | -60.48% |
| 1998 | -12.4 Million USD | -2580.0% |
| 1997 | 500 Thousand USD | -82.76% |
| 1996 | 2.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 183.8 Million USD | 24.27% |
| 2024 Q1 | 105.3 Million USD | -29.94% |
| 2024 Q2 | 147.9 Million USD | 40.46% |
| 2023 Q2 | 73.6 Million USD | 164.45% |
| 2023 FY | 250.9 Million USD | 0.76% |
| 2023 Q1 | -114.2 Million USD | -210.44% |
| 2023 Q4 | 150.3 Million USD | 6.44% |
| 2023 Q3 | 141.2 Million USD | 91.85% |
| 2022 Q1 | 3.1 Million USD | 108.54% |
| 2022 Q4 | 103.4 Million USD | 17.77% |
| 2022 Q3 | 87.8 Million USD | 60.51% |
| 2022 Q2 | 54.7 Million USD | 1664.52% |
| 2022 FY | 249 Million USD | 26.46% |
| 2021 Q3 | 44.5 Million USD | -29.14% |
| 2021 Q4 | -36.3 Million USD | -181.57% |
| 2021 Q2 | 62.8 Million USD | 99.37% |
| 2021 FY | 196.9 Million USD | -38.26% |
| 2021 Q1 | 31.5 Million USD | -56.13% |
| 2020 Q2 | 76.6 Million USD | 30.05% |
| 2020 FY | 318.9 Million USD | 45.52% |
| 2020 Q3 | -44.3 Million USD | -157.83% |
| 2020 Q4 | 71.8 Million USD | 262.08% |
| 2020 Q1 | 58.9 Million USD | 20.7% |
| 2019 FY | 219.14 Million USD | 493.98% |
| 2019 Q2 | 34.46 Million USD | 134.12% |
| 2019 Q3 | 90.09 Million USD | 161.45% |
| 2019 Q4 | 48.8 Million USD | -45.84% |
| 2019 Q1 | -100.99 Million USD | -561.79% |
| 2018 Q4 | 21.87 Million USD | -59.74% |
| 2018 Q2 | -1.85 Million USD | 95.05% |
| 2018 Q1 | -37.44 Million USD | -416.44% |
| 2018 FY | 36.89 Million USD | 128.09% |
| 2018 Q3 | 54.32 Million USD | 3033.21% |
| 2017 Q1 | -79.93 Million USD | -72.82% |
| 2017 Q3 | -5.99 Million USD | 89.53% |
| 2017 FY | -131.36 Million USD | 10.86% |
| 2017 Q4 | 11.83 Million USD | 297.4% |
| 2017 Q2 | -57.26 Million USD | 28.35% |
| 2016 FY | -147.37 Million USD | -56.44% |
| 2016 Q2 | -41.82 Million USD | -100.55% |
| 2016 Q3 | -38.43 Million USD | 8.11% |
| 2016 Q4 | -46.25 Million USD | -20.33% |
| 2016 Q1 | -20.85 Million USD | 32.17% |
| 2015 Q2 | -25.32 Million USD | -1006.73% |
| 2015 Q3 | -35.84 Million USD | -41.55% |
| 2015 Q4 | -30.74 Million USD | 14.22% |
| 2015 Q1 | -2.28 Million USD | 88.82% |
| 2015 FY | -94.2 Million USD | -46.25% |
| 2014 Q3 | -16.85 Million USD | -17.38% |
| 2014 Q4 | -20.46 Million USD | -21.42% |
| 2014 Q2 | -14.36 Million USD | -12.86% |
| 2014 FY | -64.41 Million USD | -29.66% |
| 2014 Q1 | -12.72 Million USD | -10.36% |
| 2013 Q1 | -12.97 Million USD | -251.19% |
| 2013 FY | -49.67 Million USD | -3530.8% |
| 2013 Q4 | -11.53 Million USD | 3.96% |
| 2013 Q3 | -12 Million USD | 8.82% |
| 2013 Q2 | -13.16 Million USD | -1.48% |
| 2012 Q3 | -3.96 Million USD | -187.1% |
| 2012 Q4 | 8.58 Million USD | 316.61% |
| 2012 FY | 1.44 Million USD | -95.73% |
| 2012 Q1 | -1.79 Million USD | -500.89% |
| 2012 Q2 | -1.38 Million USD | 22.99% |
| 2011 Q2 | 1.09 Million USD | -43.48% |
| 2011 Q4 | 447 Thousand USD | -98.53% |
| 2011 FY | 33.92 Million USD | 347.21% |
| 2011 Q3 | 30.44 Million USD | 2677.37% |
| 2011 Q1 | 1.93 Million USD | 1603.1% |
| 2010 Q3 | 2.46 Million USD | 141.87% |
| 2010 Q2 | -5.89 Million USD | 42.08% |
| 2010 Q1 | -10.16 Million USD | -13.24% |
| 2010 FY | -13.72 Million USD | 74.43% |
| 2010 Q4 | -129 Thousand USD | -105.23% |
| 2009 Q4 | -8.98 Million USD | 7.64% |
| 2009 Q3 | -9.72 Million USD | 38.63% |
| 2009 FY | -53.67 Million USD | 38.52% |
| 2009 Q1 | -19.12 Million USD | 37.74% |
| 2009 Q2 | -15.84 Million USD | 17.16% |
| 2008 Q1 | -20.76 Million USD | 83.85% |
| 2008 Q2 | -20.11 Million USD | 3.11% |
| 2008 Q3 | -15.7 Million USD | 21.94% |
| 2008 FY | -87.29 Million USD | 58.87% |
| 2008 Q4 | -30.71 Million USD | -95.59% |
| 2007 FY | -212.24 Million USD | -87.3% |
| 2007 Q4 | -128.59 Million USD | -346.1% |
| 2007 Q3 | -28.82 Million USD | -4.64% |
| 2007 Q2 | -27.54 Million USD | -1.0% |
| 2007 Q1 | -27.27 Million USD | -67.71% |
| 2006 Q4 | -16.26 Million USD | 59.54% |
| 2006 Q1 | -27.59 Million USD | -12.2% |
| 2006 FY | -113.31 Million USD | -351.97% |
| 2006 Q3 | -40.19 Million USD | -37.36% |
| 2006 Q2 | -29.26 Million USD | -6.05% |
| 2005 Q1 | -19.34 Million USD | 8.67% |
| 2005 FY | -25.07 Million USD | 52.09% |
| 2005 Q2 | -6.25 Million USD | 67.68% |
| 2005 Q3 | 25.12 Million USD | 501.81% |
| 2005 Q4 | -24.59 Million USD | -197.9% |
| 2004 Q4 | -21.18 Million USD | -598.91% |
| 2004 Q3 | -3.03 Million USD | 77.36% |
| 2004 Q2 | -13.38 Million USD | 9.1% |
| 2004 Q1 | -14.73 Million USD | 15.2% |
| 2004 FY | -52.33 Million USD | 10.98% |
| 2003 FY | -58.78 Million USD | 43.26% |
| 2003 Q4 | -17.37 Million USD | -27.97% |
| 2003 Q3 | -13.57 Million USD | -8.68% |
| 2003 Q2 | -12.49 Million USD | 18.64% |
| 2003 Q1 | -15.35 Million USD | 62.8% |
| 2002 FY | -103.61 Million USD | -136.12% |
| 2002 Q4 | -41.27 Million USD | -83.43% |
| 2002 Q1 | -17.82 Million USD | -15.69% |
| 2002 Q2 | -22.02 Million USD | -23.56% |
| 2002 Q3 | -22.5 Million USD | -2.18% |
| 2001 Q4 | -15.4 Million USD | -1391.2% |
| 2001 Q3 | 1.19 Million USD | 107.65% |
| 2001 Q2 | -15.59 Million USD | -10.75% |
| 2001 Q1 | -14.07 Million USD | -24.48% |
| 2001 FY | -43.88 Million USD | -23.26% |
| 2000 FY | -35.6 Million USD | -78.9% |
| 2000 Q1 | -7.22 Million USD | -44.52% |
| 2000 Q3 | -9.68 Million USD | -31.23% |
| 2000 Q4 | -11.31 Million USD | -16.78% |
| 2000 Q2 | -7.38 Million USD | -2.13% |
| 1999 FY | -19.9 Million USD | -60.48% |
| 1999 Q4 | -5 Million USD | 0.0% |
| 1999 Q2 | -5.3 Million USD | -17.78% |
| 1999 Q1 | -4.5 Million USD | -650.0% |
| 1999 Q3 | -5 Million USD | 5.66% |
| 1998 Q2 | -3.9 Million USD | -62.5% |
| 1998 Q3 | -5.4 Million USD | -38.46% |
| 1998 Q4 | -600 Thousand USD | 88.89% |
| 1998 FY | -12.4 Million USD | -2580.0% |
| 1998 Q1 | -2.4 Million USD | -84.62% |
| 1997 Q4 | -1.3 Million USD | -225.0% |
| 1997 Q1 | 3.2 Million USD | -3.03% |
| 1997 FY | 500 Thousand USD | -82.76% |
| 1997 Q3 | -400 Thousand USD | 55.56% |
| 1997 Q2 | -900 Thousand USD | -128.13% |
| 1996 Q2 | 1.3 Million USD | 750.0% |
| 1996 FY | 2.9 Million USD | 0.0% |
| 1996 Q1 | -200 Thousand USD | 0.0% |
| 1996 Q3 | -1.5 Million USD | -215.38% |
| 1996 Q4 | 3.3 Million USD | 320.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 248.303% |
| Dynavax Technologies Corporation | -37.02 Million USD | 777.595% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 306.511% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 101.782% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 4861.814% |
| Perrigo Company plc | 151.9 Million USD | -65.174% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 190.904% |
| Illumina, Inc. | -1.06 Billion USD | 123.471% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 96.342% |
| Nektar Therapeutics | -137.42 Million USD | 282.572% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 154.477% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 87.309% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 326.823% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 661.712% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -29.037% |
| Waters Corporation | 817.67 Million USD | 69.315% |
| Biogen Inc. | 1.29 Billion USD | 80.652% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 191.568% |
| Adicet Bio, Inc. | -152.03 Million USD | 265.025% |
| Evolus, Inc. | -49.23 Million USD | 609.618% |
| bluebird bio, Inc. | -244.26 Million USD | 202.718% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 357.711% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 261.285% |
| FibroGen, Inc. | -281.81 Million USD | 189.03% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 81.415% |
| Homology Medicines, Inc. | -48.25 Million USD | 619.946% |
| Geron Corporation | -193.94 Million USD | 229.367% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 188.916% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 656.599% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 441.388% |
| Myriad Genetics, Inc. | -123.7 Million USD | 302.829% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 93.8% |
| OPKO Health, Inc. | -157.02 Million USD | 259.788% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 348.842% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 148.691% |
| Zoetis Inc. | 3.06 Billion USD | 91.825% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 620.539% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 76.924% |
| Exelixis, Inc. | 170.88 Million USD | -46.824% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 94.175% |
| uniQure N.V. | -282.87 Million USD | 188.698% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 740.819% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 549.996% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 208.228% |
| Verastem, Inc. | -92.08 Million USD | 372.469% |
| Imunon, Inc. | -21.03 Million USD | 1293.033% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 170.93% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 193.681% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -133.87% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 25.676% |
| TG Therapeutics, Inc. | 20.63 Million USD | -1116.013% |
| Blueprint Medicines Corporation | -486.27 Million USD | 151.596% |
| Insmed Incorporated | -709.62 Million USD | 135.357% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 164.089% |
| Incyte Corporation | 620.52 Million USD | 59.566% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 134.54% |